Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536105 | 1.00 | YTHDC1 (0.46) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1543222 | 0.92 | G6PC1 (0.48) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1543221 | 0.92 | G6PC1 (0.48) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1543217 | 0.92 | G6PC1 (0.48) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1543349 | 0.90 | YTHDC1 (0.51) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1543347 | 0.90 | YTHDC1 (0.51) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22659191 | 0.88 | YTHDC1 (0.42) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17827173 | 0.84 | YTHDC1 (0.36) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17827164 | 0.80 | YTHDC1 (0.33) | YTHDC1G6PC1SLC6A2SLC6A4DPP8 | |
| SCHEMBL3376962 | 0.78 | YTHDC1 (0.58) | YTHDC1G6PC1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| CN-104592231-A | Novel Tricyclic Compounds | ABBVIE INC | 2015-05-06 | — | — | CN | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152133-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | YTHDC1 4818/4885G6PC1 1238/4885SLC6A2 1464/4885 |
| US-20090312338-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | YTHDC1 4818/4885G6PC1 1238/4885SLC6A2 1464/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | YTHDC1 4818/4885G6PC1 1238/4885SLC6A2 1464/4885 |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | YTHDC1 4818/4885G6PC1 1238/4885SLC6A2 1464/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | YTHDC1 4818/4885G6PC1 1238/4885SLC6A2 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.